BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study

MT Newswires Live

05/18

BioMarin Pharmaceutical's (BMRN) Phase 3 ENERGY 3 trial of BMN 401 in children with ENPP1 deficiency met one of two co-primary endpoints but did not show improvement in key clinical outcomes, the company said Monday.

The study showed a statistically significant increase in plasma inorganic pyrophosphate levels but did not improve Radiographic Global Impression of Change scores, the primary measure of rickets severity.

The company added that no notable trends were observed in secondary endpoints, and the therapy was generally well tolerated with no new safety concerns reported.

Shares of BioMarin Pharmaceutical were down over 1% in Monday trading.

Price: 51.27, Change: -0.55, Percent Change: -1.05

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2636079079"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2636079079\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2636079079?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636079079","market":"sg","top_or_hot":-1,"title":"BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study","media":"MT Newswires Live","content":"<html><body><p> BioMarin Pharmaceutical's (BMRN) Phase 3 ENERGY 3 trial of BMN 401 in children with ENPP1 deficiency met one of two co-primary endpoints but did not show improvement in key clinical outcomes, the company said Monday.</p><p>The study showed a statistically significant increase in plasma inorganic pyrophosphate levels but did not improve Radiographic Global Impression of Change scores, the primary measure of rickets severity.</p><p>The company added that no notable trends were observed in secondary endpoints, and the therapy was generally well tolerated with no new safety concerns reported.</p><p>Shares of BioMarin Pharmaceutical were down over 1% in Monday trading.</p><p>Price: 51.27, Change: -0.55, Percent Change: -1.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-05-18 21:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> BioMarin Pharmaceutical's (BMRN) Phase 3 ENERGY 3 trial of BMN 401 in children with ENPP1 deficiency met one of two co-primary endpoints but did not show improvement in key clinical outcomes, the company said Monday.</p><p>The study showed a statistically significant increase in plasma inorganic pyrophosphate levels but did not improve Radiographic Global Impression of Change scores, the primary measure of rickets severity.</p><p>The company added that no notable trends were observed in secondary endpoints, and the therapy was generally well tolerated with no new safety concerns reported.</p><p>Shares of BioMarin Pharmaceutical were down over 1% in Monday trading.</p><p>Price: 51.27, Change: -0.55, Percent Change: -1.05</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMRN.AU","symbol_name":"Ballymore Resources Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636079079","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636079079","pubTimestamp":1779112222,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioMarin Pharmaceutical's  Phase 3 ENERGY 3 trial of BMN 401 in children with ENPP1 deficiency met one of two co-primary endpoints but did not show improvement in key clinical outcomes, the company said Monday.The study showed a statistically significant increase in plasma inorganic pyrophosphate levels but did not improve Radiographic Global Impression of Change scores, the primary measure of rickets severity.The company added that no notable trends were observed in secondary endpoints, and the therapy was generally well tolerated with no new safety concerns reported.Shares of BioMarin Pharmaceutical were down over 1% in Monday trading.Price: 51.27, Change: -0.55, Percent Change: -1.05","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMRN.AU":"Ballymore Resources Ltd","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4139":"生物科技","BMRN":"拜玛林制药","BK7095":"多种金属与采矿","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BMN":"BlackRock 2037 Municipal Target Term","BK4566":"资本集团","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H"},"translate_title":"拜玛林制药报告BMN 401 ENPP1缺乏症研究无功能改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN.AU":1,"BMRN":1,"BMN":1.5},"content_text":"BioMarin Pharmaceutical's (BMRN) Phase 3 ENERGY 3 trial of BMN 401 in children with ENPP1 deficiency met one of two co-primary endpoints but did not show improvement in key clinical outcomes, the company said Monday.The study showed a statistically significant increase in plasma inorganic pyrophosphate levels but did not improve Radiographic Global Impression of Change scores, the primary measure of rickets severity.The company added that no notable trends were observed in secondary endpoints, and the therapy was generally well tolerated with no new safety concerns reported.Shares of BioMarin Pharmaceutical were down over 1% in Monday trading.Price: 51.27, Change: -0.55, Percent Change: -1.05","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}